TrialAnnals of oncology : official journal of the European Society for Medical Oncology2016

A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer.

M E Lacouture et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.